The device offers crucial information related to the clot feature for physicians to implement more informed decisions. Credit: Freedomz / Shutterstock.com.

Medical device company Sensome has collaborated with Japanese guidewire company Asahi Intecc for the development of the next-generation ClotildSmart Guidewire.

Under the collaboration, Asahi Intecc will be responsible for the manufacturing of the device.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

This device is intended to treat acute ischemic stroke, which is the major cause of acquired long-term disability.

Clotild is Sensome’s connected neurovascular guidewire developed for providing blood clot characterisation during the endovascular management of acute ischemic stroke. It is currently under assessment in a clinical study.

Asahi Intecc CEO Masahiko Miyata said: “By combining Asahi’s guidewire design and manufacturing technology and experience with Sensome’s core competencies, the companies position themselves to create a new generation of smart guidewires at a high level of performance, reliability and consequently, value to physicians and patients.”

See Also:

Clotild incorporates Sensome’s artificial intelligence-powered tissue micro-sensor.

This device offers crucial information related to the clot feature for physicians to implement more informed decisions during the procedure.

Furthermore, the tissue sensing technology has the capability to integrate into minimally invasive medical devices used in other treatment areas, including oncology and peripheral vascular disease.

Sensome CEO Franz Bozsa said: “This collaboration underscores our dedication to pioneering smart medical devices designed to address the present shortcomings of minimally invasive procedures in partnership with world-class medical device manufacturers.”